Updates in the medical management of Parkinson disease.
Most, if not all, currently available drugs for Parkinson disease address dopaminergic loss and relieve symptoms. However, their adverse effects can be limiting and they do not address disease progression. Moreover, nonmotor features of Parkinson disease such as depression, dementia, and psychosis are now recognized as important and disabling. A cure remains elusive. However, promising interventions and agents are emerging. As an example, people who exercise regularly are less likely to develop Parkinson disease, and if they develop it, they tend to have slower progression.
Center for Neurological Restoration, S31, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. fernanH@ccf.org
Hubert H
HH
Fernandez
D000367:Age Factors; D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001058:Apomorphine / Q000627:therapeutic use; D002394:Catechol O-Methyltransferase; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D018450:Disease Progression; D015259:Dopamine Agents / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008995:Monoamine Oxidase; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology
D000978:Antiparkinson Agents; D018680:Cholinergic Antagonists; D015259:Dopamine Agents; D007980:Levodopa; D000547:Amantadine; D008995:Monoamine Oxidase; D002394:Catechol O-Methyltransferase; D001058:Apomorphine